Primary clinical endpoint reached

0

The LixiLan-L Phase III clinical trial sponsored by Sanofi met its primary endpoint in patients with type 2 diabetes treated with insulin glargine with or without metformin. The fixed-ratio combination of insulin glargine 100 Units/mL and lixisenatide, a GLP-1 receptor agonist, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared with insulin glargine 100 Units/mL. Overall, the fixed-ratio combination had a safety profile reflecting those of insulin glargine 100 Units/mL and lixisenatide.

Regulatory submissions are planned for Q4 2015 in the United States and Q1 2016 in the European Union.

SHARE

LEAVE A REPLY

Please enter your comment!
Please enter your name here